Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
01/02/19 Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference
12/17/18 Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
11/30/18 Statement by Richard Pops, Chairman and CEO of Alkermes on the Annual CDC Report on Drug Overdose Deaths and Suicide Mortality in the United States
11/29/18 Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
11/06/18 Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
11/06/18 Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
11/01/18 Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
11/01/18 Trading in Alkermes Ordinary Shares Halted Today
10/29/18 Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
10/26/18 Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®
10/23/18 Alkermes Plc Reports Third Quarter 2018 Financial Results
10/17/18 Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress
10/16/18 Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results
09/10/18 Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
09/05/18 Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
Displaying 91 - 105 of 795